📢 𝐂𝐚𝐥𝐥 𝐟𝐨𝐫 𝐀𝐛𝐬𝐭𝐫𝐚𝐜𝐭𝐬 – 𝐕𝐏𝐇 𝟐𝟎𝟐𝟔 | 𝐍𝐎𝐖 𝐎𝐏𝐄𝐍!

We are excited to share that our Group Leader Prof. Francesco Pappalardo serve as Chair of the Track “𝘊𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘈𝘐-𝘥𝘳𝘪𝘷𝘦𝘯 𝘋𝘳𝘶𝘨 𝘋𝘦𝘭𝘪𝘷𝘦𝘳𝘺 𝘢𝘯𝘥 𝘋𝘦𝘴𝘪𝘨𝘯” at the 𝟗𝐭𝐡 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐏𝐡𝐲𝐬𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐇𝐮𝐦𝐚𝐧 (𝐕𝐏𝐇 𝟐𝟎𝟐𝟔)

This is a fantastic opportunity to contribute and engage in discussions on computational and AI-driven approaches in drug delivery and drug design, within one of the leading conferences in the field

📝 𝐀𝐛𝐬𝐭𝐫𝐚𝐜𝐭 𝐬𝐮𝐛𝐦𝐢𝐬𝐬𝐢𝐨𝐧𝐬 𝐚𝐫𝐞 𝐧𝐨𝐰 𝐨𝐩𝐞𝐧 𝐮𝐧𝐭𝐢𝐥 𝐌𝐚𝐫𝐜𝐡 𝟐
🔗 https://vph-conference.org/abstract-submission/

📌 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄
9th International Conference on the Virtual Physiological Human (VPH)
🗓 September 1–4, 2026
📍 Politecnico di Milano
🔗 https://vph-conference.org

🚀 𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝟐𝐧𝐝 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐨𝐧𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 (𝐚𝐢𝐇𝐞𝐚𝐥𝐭𝐡𝟐𝟎𝟐𝟓)
📅 𝟏𝟎–𝟏𝟏 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓
📍 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 𝐨𝐟 𝐀𝐩𝐩𝐥𝐢𝐞𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐚𝐧𝐝 𝐀𝐫𝐭𝐬 𝐍𝐨𝐫𝐭𝐡𝐰𝐞𝐬𝐭𝐞𝐫𝐧 𝐒𝐰𝐢𝐭𝐳𝐞𝐫𝐥𝐚𝐧𝐝 𝐅𝐇𝐍𝐖 (𝐌𝐮𝐭𝐭𝐞𝐧𝐳), 𝐁𝐚𝐬𝐞𝐥, 𝐒𝐰𝐢𝐭𝐳𝐞𝐫𝐥𝐚𝐧𝐝

Over one and a half days, 𝐚𝐢𝐇𝐞𝐚𝐥𝐭𝐡𝟐𝟎𝟐𝟓 will offer a journey into the future of healthcare, exploring how artificial intelligence is transforming diagnostics, therapeutics, and public health — reaching the frontier of 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐭𝐰𝐢𝐧𝐬 and 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞

🧠 Among the many outstanding contributions, we are proud to highlight the 𝐊𝐞𝐲𝐧𝐨𝐭𝐞 𝐋𝐞𝐜𝐭𝐮𝐫𝐞 by our 𝐆𝐫𝐨𝐮𝐩𝐋𝐞𝐚𝐝𝐞𝐫, 𝐏𝐫𝐨𝐟. Francesco Pappalardo
(𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 𝐨𝐟 𝐂𝐚𝐭𝐚𝐧𝐢𝐚, 𝐈𝐭𝐚𝐥𝐲):
🎤 “𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 𝘐𝘯 𝘚𝘪𝘭𝘪𝘤𝘰 𝘢𝘵 𝘵𝘩𝘦 𝘊𝘳𝘰𝘴𝘴𝘳𝘰𝘢𝘥𝘴: 𝘚𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘔𝘢𝘵𝘶𝘳𝘪𝘵𝘺 𝘢𝘯𝘥 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘙𝘦𝘢𝘥𝘪𝘯𝘦𝘴𝘴”

A must-attend event for anyone involved in 𝐀𝐈 𝐢𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞, 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐬𝐜𝐢𝐞𝐧𝐜𝐞, and 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧

👉 𝐕𝐢𝐞𝐰 𝐭𝐡𝐞 𝐏𝐫𝐨𝐠𝐫𝐚𝐦
👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰 to join and follow the conference
👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮𝐫 𝐭𝐞𝐚𝐦
👉 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧

Join us in writing the next chapter in the history of digital medicine

𝐈𝐧𝐧𝐨𝐯𝐚𝐳𝐢𝐨𝐧𝐞 𝐞 𝐢𝐧𝐭𝐞𝐫𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐚𝐫𝐢𝐭à 𝐧𝐞𝐥𝐥𝐚 𝐫𝐢𝐜𝐞𝐫𝐜𝐚 𝐛𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚

Siamo entusiasti di annunciare il workshop 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐧𝐞𝐭𝐰𝐨𝐫𝐤 un’occasione unica per esplorare le 𝐧𝐮𝐨𝐯𝐞 𝐟𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐞 𝐝𝐞𝐥𝐥𝐚 𝐫𝐢𝐜𝐞𝐫𝐜𝐚 𝐛𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚 attraverso il dialogo tra 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐚, 𝐛𝐢𝐨𝐜𝐡𝐢𝐦𝐢𝐜𝐚, 𝐜𝐡𝐢𝐦𝐢𝐜𝐚 𝐟𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚 𝐞 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐳𝐚 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥𝐞.

Tra i temi al centro del dibattito:

la 𝐦𝐨𝐝𝐮𝐥𝐚𝐳𝐢𝐨𝐧𝐞 𝐝𝐞𝐥𝐥𝐚 𝐟𝐞𝐫𝐫𝐨𝐩𝐭𝐨𝐬𝐢 come strategia terapeutica per malattie neurodegenerative e tumorali;

Al centro dell’intervento dedicato alle “𝐍𝐞𝐰 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐌𝐞𝐭𝐡𝐨𝐝𝐨𝐥𝐨𝐠𝐢𝐞𝐬” ci sarà la 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐚 𝐢𝐧 𝐬𝐢𝐥𝐢𝐜𝐨, che insieme ai modelli complessi in vitro apre nuove prospettive per una 𝐫𝐢𝐜𝐞𝐫𝐜𝐚 𝐛𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚 𝐩𝐢ù 𝐩𝐫𝐞𝐝𝐢𝐭𝐭𝐢𝐯𝐚, 𝐞𝐭𝐢𝐜𝐚 𝐞𝐬𝐨𝐬𝐭𝐞𝐧𝐢𝐛𝐢𝐥𝐞, capace di migliorare la 𝐫𝐢𝐥𝐞𝐯𝐚𝐧𝐳𝐚 𝐭𝐫𝐚𝐬𝐥𝐚𝐳𝐢𝐨𝐧𝐚𝐥𝐞 dei risultati scientifici.

il legame tra 𝐜𝐡𝐢𝐦𝐢𝐜𝐚 𝐟𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚 e 𝐢𝐧𝐧𝐨𝐯𝐚𝐳𝐢𝐨𝐧𝐞 𝐭𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐚;

l’uso di 𝐀𝐈 𝐞 𝐝𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐳𝐳𝐚𝐳𝐢𝐨𝐧𝐞 per scoprire nuovi composti bioattivi.

L’iniziativa riflette pienamente la missione di 𝐒𝐀𝐅𝐈³, che promuove ricerca e formazione avanzata in un contesto internazionale.

𝟐𝟕 𝐍𝐨𝐯𝐞𝐦𝐛𝐫𝐞 𝟐𝟎𝟐𝟓
𝟏𝟓:𝟎𝟎 – 𝟏𝟗.𝟎𝟎
𝐀𝐮𝐥𝐚 𝐌𝐚𝐠𝐧𝐚 𝐒𝐜𝐮𝐨𝐥𝐚 𝐒𝐮𝐩𝐞𝐫𝐢𝐨𝐫𝐞 – Villa San Saverio, Via Valdisavoia 9 – Catania (CT)

Maggiori informazioni: https://safi3.it/frontiers-in-drug-development-and…/#SAFI3Università di Catania

We’re excited to announce the workshop Frontiers in Drug Development and Molecular Network — a unique opportunity to explore the new frontiers of biomedical research through dialogue between biology, biochemistry, pharmaceutical chemistry, and artificial intelligence.

Among the key topics of discussion:

Modulation of ferroptosis as a therapeutic strategy for neurodegenerative and cancer diseases;

The session on “New Approach Methodologies” will focus on in silico medicine, which—together with advanced in vitro models—opens new perspectives for a more predictive, ethical, and sustainable biomedical research, enhancing the translational relevance of scientific outcomes;

The connection between pharmaceutical chemistry and therapeutic innovation;

The use of AI and digital technologies to accelerate the discovery of new bioactive compounds.

This initiative fully reflects the mission of SAFI³, which promotes advanced training and interdisciplinary research in an international context.

November 27, 2025
3:00 PM – 7:00 PM
Aula Magna, Scuola Superiore – Villa San Saverio, Via Valdisavoia 9, Catania (CT)

More information:https://safi3.it/frontiers-in-drug-development-and…/

🎀 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 𝐢𝐬 𝐜𝐨𝐦𝐢𝐧𝐠 𝐭𝐨 𝐚 𝐜𝐥𝐨𝐬𝐞, 𝐛𝐮𝐭 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐞𝐯𝐞𝐫𝐲 𝐝𝐚𝐲
𝐈𝐧 𝐬𝐢𝐥𝐢𝐜𝐨 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 uses mathematical models and computer simulations to study diseases and therapies.
In breast cancer, this approach can:
✨ Predict individual drug response
✨ Optimize therapeutic combinations
✨ Reduce invasive testing
✨ Shorten research timelines

It’s like having a patient’s “digital twin,” allowing different scenarios to be tested and the best strategy to be chosen

This is the path of 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: more personalized, safer, faster

📌 Within this perspective, the research project was launched:
𝐂𝐨𝐦𝐩𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐌𝐨𝐝𝐞𝐥𝐥𝐢𝐧𝐠 𝐅𝐨𝐫 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧 𝐎𝐟 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐈𝐧 𝐄𝐚𝐫𝐥𝐲 𝐒𝐭𝐚𝐠𝐞 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬𝐑𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐍𝐞𝐨𝐚𝐝𝐣𝐮𝐯𝐚𝐧𝐭 𝐂𝐡𝐞𝐦𝐨-𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 𝐀 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 𝐎𝐛𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐒𝐭𝐮𝐝𝐲
(Coordinated by Dr. Giuseppe Catanuto – Humanitas)

👉 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐨𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞𝐬 𝐚𝐧𝐝 𝐝𝐞𝐬𝐢𝐠𝐧

𝐒𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐡𝐲𝐩𝐨𝐭𝐡𝐞𝐬𝐢𝐬
It is hypothesized that, using a predictive model based on UISS, it will be possible to anticipate clinical outcomes in patients with TNBC (triple-negative breast cancer) treated with chemo-immunotherapy

𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐨𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞
• Prediction of treatment activity based on UISS, according to pCR rates (defined as pathological stage ypT0/Tis ypN0 at the time of definitive surgery)

𝐒𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐨𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞𝐬
• UISS-based prediction of survival outcomes according to Event Free Survival (EFS), defined as the time from randomization to local or distant recurrence, second primary cancer, or death

A concrete step toward 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 that increasingly meets the needs of patients

 UISS al Parlamento Europeo: l’eccellenza scientifica “made in UniCT” protagonista a Bruxelles! 

Il progetto UISS – Universal Immune System Simulator, sviluppato dal Prof. Francesco Pappalardo con il supporto del Gruppo COMBINE del Dipartimento di Scienze del Farmaco e della Salute dell’Università di Catania, è stato recentemente presentato al Parlamento Europeo durante “Excellence in Health Science”, evento promosso dal Committee on Public Health (SANT)

A rappresentarlo, la Prof.ssa Liesbet Geris (KU Leuven, Université de Liège), direttrice esecutiva della Virtual Physiological Human (VPH) Initiative, che ha incluso UISS tra le innovazioni più avanzate nel campo della salute digitale e della medicina personalizzata.

UISS è oggi il modello computerizzato più evoluto al mondo per studiare le risposte del sistema immunitario umano a vaccini, malattie autoimmuni e terapie oncologiche. Basato su tecniche di agent-based modeling e integrando dati clinici reali, consente di:

• prevedere l’efficacia di vaccini e terapie innovative,
• ridurre tempi e costi della ricerca biomedica,
• promuovere la medicina personalizzata.

Dal 2004, UISS è al centro di numerosi progetti europei e internazionali e nel 2024 ha ottenuto un riconoscimento storico da parte dell’European Medicines Agency (EMA) come primo approccio meccanicistico supportato a livello regolatorio — un passo fondamentale verso l’uso dei modelli in silico per guidare le decisioni su vaccini e terapie.

Un risultato che conferma la capacità della ricerca italiana di incidere nel panorama scientifico internazionale e di contribuire alla costruzione di una sanità più rapida, mirata e sostenibile.

🎀 October is Breast Cancer Awareness Month

We at the Combine Group, Università di Catania Department of Drug and Health Sciences, join this awareness campaign with our contribution from the world of 𝐢𝐧 𝐬𝐢𝐥𝐢𝐜𝐨 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞

Throughout this month, we will share insights, data, and perspectives on how research and new technologies can support prevention and treatment.

💡Prevention starts with information

👉 Follow us on LinkedIn Combine Group

𝟖 𝐌𝐚𝐠𝐠𝐢𝐨 𝟐𝟎𝟐𝟓 – 𝐏𝐇𝐀𝐑𝐌𝐀 𝐃𝐀𝐘 𝐃𝐢𝐩𝐚𝐫𝐭𝐢𝐦𝐞𝐧𝐭𝐨 𝐝𝐢 𝐒𝐜𝐢𝐞𝐧𝐳𝐞 𝐝𝐞𝐥 𝐅𝐚𝐫𝐦𝐚𝐜𝐨 𝐞 𝐝𝐞𝐥𝐥𝐚 𝐒𝐚𝐥𝐮𝐭𝐞, 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭à 𝐝𝐢𝐂𝐚𝐭𝐚𝐧𝐢𝐚

Una giornata ricca di confronto e innovazione quella del Pharma Day, che ha visto protagonisti studenti, docenti e ricercatori del Dipartimento di Scienze del Farmaco e della Salute  dell’ Università di Catania

Anche il 𝐂𝐨𝐦𝐛𝐢𝐧𝐞 𝐆𝐫𝐨𝐮𝐩 ha avuto il piacere di presentare una serie di 𝐩𝐨𝐬𝐭𝐞𝐫 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐢, illustrando le attività di ricerca in ambito farmacologico e computazionale, con un focus su 𝐦𝐨𝐝𝐞𝐥𝐥𝐢 𝐩𝐫𝐞𝐝𝐢𝐭𝐭𝐢𝐯𝐢 e 𝐬𝐢𝐦𝐮𝐥𝐚𝐳𝐢𝐨𝐧𝐢 𝐚𝐯𝐚𝐧𝐳𝐚𝐭𝐞.

Nel pomeriggio si è tenuto un intervento incentrato sul 𝐬𝐢𝐦𝐮𝐥𝐚𝐭𝐨𝐫𝐞 𝐔𝐈𝐒𝐒 (𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐞 𝐒𝐲𝐬𝐭𝐞𝐦𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐨𝐫), sviluppato all’interno del Combine Group. Durante la presentazione sono state illustrate le sue potenzialità come strumento avanzato per la 𝐫𝐢𝐜𝐞𝐫𝐜𝐚 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚 𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚, in particolare nel contesto della 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐚 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐳𝐚𝐭𝐚 e della valutazione di 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞 𝐭𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐡𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞.

Tra i punti salienti, è stato evidenziato che 𝐮𝐧𝐚 𝐬𝐨𝐥𝐮𝐳𝐢𝐨𝐧𝐞 𝐔𝐈𝐒𝐒 𝐝𝐞𝐝𝐢𝐜𝐚𝐭𝐚 𝐚𝐥𝐥𝐚 𝐭𝐮𝐛𝐞𝐫𝐜𝐨𝐥𝐨𝐬𝐢 (𝐔𝐈𝐒𝐒-𝐓𝐁) 𝐡𝐚 𝐫𝐢𝐜𝐞𝐯𝐮𝐭𝐨 𝐮𝐧𝐚 𝐥𝐞𝐭𝐭𝐞𝐫𝐚 𝐝𝐢 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐨 𝐝𝐚 𝐩𝐚𝐫𝐭𝐞 𝐝𝐞𝐥𝐥’𝐄𝐌𝐀 (𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐀𝐠𝐞𝐧𝐜𝐲), riconoscendone il valore scientifico e applicativo.

Un sentito ringraziamento a tutti i partecipanti per aver contribuito a rendere il Pharma Day un’occasione di 𝐜𝐫𝐞𝐬𝐜𝐢𝐭𝐚, 𝐜𝐨𝐧𝐝𝐢𝐯𝐢𝐬𝐢𝐨𝐧𝐞 𝐞 𝐢𝐬𝐩𝐢𝐫𝐚𝐳𝐢𝐨𝐧𝐞 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚.

Prof Francesco Pappalardo Explores Innovative In Silico Approaches at Biomathematics Workshop

The workshop “New Trends in Biomathematics – Applications in Oncology and Immunology” was held today, June 21, 2024, at Università degli Studi Mediterranea di Reggio Calabria. This event brought together experts and enthusiasts from various fields to discuss the latest advancements in the application of mathematical models to medical research.

🎙️ Presentations by Prof. Francesco Pappalardo:

Beyond the Data: Computational Modeling as a Tool in Oncology and Immunology
Simulating to Predict: Computational Models in Infectious Diseases
Prof. Francesco Pappalardo’s presentations highlighted the transformative potential of in silico medicine, a field that uses computational models to simulate biological processes. These techniques promise to revolutionize healthcare by reducing the costs and time required for drug development.

🔹 Key Insights:

In Silico Medicine: Prof. Pappalardo illustrated how computational modeling can enhance our understanding of disease mechanisms, optimize drug development, and personalize treatments.
Revolutionizing Healthcare: By simulating clinical trials and predicting treatment outcomes, in silico methods offer a more efficient and ethical approach to medical research.
The workshop aimed to review the state of the art in mathematics applied to oncology and immunology, identifying emerging trends and strategies to advance the field. This gathering was of significant interest not only to experts in mathematical modeling and bioinformatics but also to doctors, biologists, and researchers in life and health sciences.

🔬 The event underscored the importance of interdisciplinary collaboration in pushing the boundaries of medical research. By integrating computational techniques with traditional medical practices, we can look forward to a future where healthcare is more precise, efficient, and personalized.

Stay tuned for more updates on the latest trends and breakthroughs in biomathematics and its applications in medicine.

Join Us for an Exciting Event on Pharmaceutical Research!

On Wednesday, May 15th, at 12:00 PM, in Classroom F (Building 2, University City), don’t miss the chance to meet Professor Francesco Pappalardo and Professor Giulia Russo from the DSFS! 🎓

🔍 Event Theme: “Impact of In Silico Trials on the Pharmaceutical World: Regulatory Challenges and Opportunities for Pharmaceutical and Health Sciences Students.” 📊

🧠 Discover the revolutionary Universal Immune System Simulator (UISS), developed by the Combine Group. This cutting-edge computational framework promises to transform the pharmaceutical industry! 💡

From predicting vaccination strategies to identifying molecular targets to overcome drug resistance, UISS offers a broad spectrum of possibilities that will revolutionize the future of pharmaceutical research. 💊

👩‍🔬 Students, especially those in the final years of their degree programs, are encouraged to attend and immerse themselves in this field of excellence from our department. Don’t miss out! 🚀

PharmaceuticalResearch #InSilico #UISS #DSFS #UniversityOfCatania

First annual meeting (Switzerland, 2024)

Welcome to our latest update on the groundbreaking initiatives in tuberculosis research! As we delve into the world of tuberculosis consortium partnerships, we are excited to share the progress made in developing novel therapeutic options, improving outcomes, and preventing relapse. Our collaborative efforts aim to bring about transformative changes in tuberculosis treatment, with a focus on shortening treatment duration.

⚕ In Vivo Evaluation of Immunotherapies

A major focus of our research involves the in vivo evaluation of the most promising immunotherapies. By combining these therapies with traditional approaches like chemotherapy or therapeutic vaccines, we aim to enhance their efficacy and potentially shorten the overall treatment duration. This approach holds great promise in revolutionizing tuberculosis treatment protocols.

⚕ In Silico Modeling for Preclinical Progression

Harnessing the power of technology, our consortium employs in silico modeling to facilitate both in vitro and in vivo preclinical progression. This cutting-edge approach allows us to simulate and predict the therapeutic effects of potential treatments in the clinic. By utilizing advanced computational methods, we can streamline the research process, saving valuable time and resources.

One of the Goals: Develop Novel Therapeutic Options

Our consortium is committed to pushing the boundaries of tuberculosis research by developing innovative therapeutic options. The goal is to create treatments that not only effectively combat the disease but also have the potential to significantly reduce the duration of treatment. By leveraging the collective expertise of our partners, we are exploring new avenues for drug development and testing.

⚕ Improve Outcomes and Prevent Relapse

Achieving better outcomes for tuberculosis patients is at the forefront of our collaborative efforts. We are dedicated to identifying strategies that not only cure the infection but also prevent relapses. Our consortium recognizes the importance of sustained recovery, and our research is geared towards finding solutions that ensure long-term success in tuberculosis treatment.

⚗ Reflecting on Achievements and Future Goals

As we come together to discuss the accomplishments of the past year, we express our gratitude for the opportunity to collaborate and make significant strides in tuberculosis research. Our consortium’s dedication to advancing the field is evident in the milestones achieved, from the development of novel therapeutic options to the successful in vivo evaluation of immunotherapies.

Looking ahead, our future goals include expanding our collaborative efforts, integrating new research findings, and continuously striving for innovative solutions to combat tuberculosis. We are excited about the possibilities that lie ahead and are confident that our collective endeavors will contribute to the global fight against this infectious disease.

In conclusion, our tuberculosis consortium is making significant progress in reshaping the landscape of tuberculosis research. By fostering collaboration, embracing innovation, and reflecting on our achievements, we are committed to bringing about positive change in the lives of those affected by tuberculosis. Together, we are on the path to transforming the future of tuberculosis treatment. Thank you for your ongoing support and partnership in this important endeavor.

Pint of Science 2023

È possibile creare una replica digitale di un paziente, in grado di anticipare le variazioni nel suo stato di salute e fornire un valido supporto decisionale per la gestione clinica? Grazie agli avanzamenti nelle tecnologie informatiche di ultima generazione, oggi possiamo integrare e analizzare tutte le informazioni disponibili per un singolo paziente, consentendoci di predire l’andamento della sua salute in specifiche condizioni. Il Professor Francesco Pappalardo approfondirà questo argomento e altri aspetti affascinanti, il tutto in un’atmosfera informale, davanti a una piacevole pinta di birra

---

---

Sharper Night

Catania ha recentemente celebrato e sottolineato l’importanza della ricerca attraverso la partecipazione alla Notte Europea dei Ricercatori. La città ha ideato un ricco programma che abbraccia una vasta gamma di temi, spaziando dalla ricerca di base alle applicazioni tecnologiche in campi diversificati. L’interdisciplinarietà e le sfide per il futuro hanno guidato l’intero programma, creando un filo conduttore che ha accentuato la diversità e la portata delle iniziative presentate durante l’evento.

Event link: https://www.sharper-night.it/evento/conferenza-universita-imprenditoriale/

---

4 April 2023 – Les Diablerets (Switzerland)

UISS, il paziente virtuale – Radio24 (IlSole24Ore)